Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$13.13 +0.7%	$12.83	$8.46 ▼ $19.09	$1.75B	1.48	734,812 shs	817,525 shs
ETON Eton Pharmaceuticals	$14.01 +0.4%	$16.64	$3.22 ▼ $21.48	$375.72M	1.28	252,086 shs	4.39 million shs
GLPG Galapagos	$27.98 -0.3%	$27.57	$22.36 ▼ $31.23	N/A	0.07	251,595 shs	183,086 shs
IDYA IDEAYA Biosciences	$21.37 -4.1%	$20.05	$13.45 ▼ $44.42	$1.87B	0.04	1.03 million shs	3.20 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	+0.69%	+5.63%	+1.39%	-10.01%	+46.05%
ETON Eton Pharmaceuticals	+0.36%	+3.24%	-30.23%	+7.60%	+316.96%
GLPG Galapagos	-0.32%	+2.04%	-3.95%	+9.90%	+11.30%
IDYA IDEAYA Biosciences	-4.13%	-1.38%	+9.25%	+25.34%	-38.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTA Centessa Pharmaceuticals	3.088 of 5 stars	3.5	3.0	0.0	2.0	3.3	0.6
ETON Eton Pharmaceuticals	2.5913 of 5 stars	3.5	3.0	0.0	2.0	1.7	0.6
GLPG Galapagos	0.3502 of 5 stars	0.8	3.0	0.0	1.9	0.0	0.6
IDYA IDEAYA Biosciences	3.604 of 5 stars	3.5	1.0	4.4	1.9	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	3.00	Buy	$27.89	112.41% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	111.75% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-9.46% Downside
IDYA IDEAYA Biosciences	2.93	Moderate Buy	$53.42	149.96% Upside

Current Analyst Ratings Breakdown

Latest ETON, CNTA, IDYA, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
6/26/2025	IDYA IDEAYA Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$44.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/28/2025	CNTA Centessa Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
5/22/2025	IDYA IDEAYA Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$63.00 ➝ $66.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/14/2025	ETON Eton Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$26.00 ➝ $28.00
5/8/2025	CNTA Centessa Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform ➝ Outperform	$6.00
5/8/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
3/31/2025	CNTA Centessa Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$38.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	$6.85M	255.99	N/A	N/A	$3.05 per share	4.30
ETON Eton Pharmaceuticals	$39.01M	9.63	N/A	N/A	$0.94 per share	14.90
GLPG Galapagos	$298.31M	N/A	$0.73 per share	38.54	$47.57 per share	N/A
IDYA IDEAYA Biosciences	$7M	267.37	N/A	N/A	$12.25 per share	1.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.18	N/A	28.02	N/A	-9.49%	-3.15%	-1.08%	8/4/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
IDYA IDEAYA Biosciences	-$274.48M	-$3.59	N/A	N/A	N/A	N/A	-29.28%	-27.68%	8/5/2025 (Estimated)

Latest ETON, CNTA, IDYA, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A
5/6/2025	Q1 2025	IDYA IDEAYA Biosciences	-$0.75	-$0.82	-$0.07	-$0.82	$2.10 million	N/A
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
ETON Eton Pharmaceuticals	1.23	1.97	1.43
GLPG Galapagos	N/A	7.95	7.86
IDYA IDEAYA Biosciences	N/A	13.92	13.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
ETON Eton Pharmaceuticals	27.86%
GLPG Galapagos	32.46%
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	7.09%
ETON Eton Pharmaceuticals	16.03%
GLPG Galapagos	2.91%
IDYA IDEAYA Biosciences	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	133.55 million	124.09 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
GLPG Galapagos	1,310	N/A	N/A	Optionable
IDYA IDEAYA Biosciences	80	87.58 million	85.39 million	Optionable

ETON, CNTA, IDYA, and GLPG Headlines

Recent News About These Companies

IDEAYA Biosciences (NASDAQ:IDYA) Earns Overweight Rating from Analysts at Wells Fargo & Company

June 28 at 2:24 AM | americanbankingnews.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 27 at 6:00 AM | prnewswire.com

IDEAYA Biosciences (NASDAQ:IDYA) Rating Increased to Strong-Buy at Wells Fargo & Company

June 27 at 5:55 AM | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) Stock, Short Interest Report

June 27 at 4:15 AM | benzinga.com

Wells Fargo Initiates Coverage of IDEAYA Biosciences (IDYA) with Overweight Recommendation

June 27 at 4:15 AM | msn.com

IDEAYA Biosciences (NASDAQ:IDYA) Stock, Insider Trading Activity

June 26 at 4:51 PM | benzinga.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Average Price Target from Analysts

June 19, 2025 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" from Brokerages

June 16, 2025 | marketbeat.com

Here's Why Steve Cohen's Point72 Recently Shelled Out Over $100M for Two Biopharma Stocks

June 10, 2025 | msn.com

Cantor Fitzgerald Forecasts IDYA FY2026 Earnings

June 10, 2025 | marketbeat.com

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events

June 2, 2025 | prnewswire.com

Millennium Management LLC Cuts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

June 1, 2025 | marketbeat.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | prnewswire.com

January 2026 Options Now Available For IDEAYA Biosciences

May 17, 2025 | nasdaq.com

A Look At The Fair Value Of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

May 10, 2025 | finance.yahoo.com

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business ...

May 6, 2025 | gurufocus.com

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025 | gurufocus.com

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025 | prnewswire.com

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors

May 6, 2025 | prnewswire.com

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events

April 28, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON, CNTA, IDYA, and GLPG Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

$13.13 +0.09 (+0.69%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$13.14 +0.01 (+0.08%)

As of 06/27/2025 06:20 PM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Eton Pharmaceuticals NASDAQ:ETON

$14.01 +0.05 (+0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$14.03 +0.02 (+0.14%)

As of 06/27/2025 05:50 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Galapagos NASDAQ:GLPG

$27.98 -0.09 (-0.32%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$27.99 +0.01 (+0.04%)

As of 06/27/2025 04:32 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

IDEAYA Biosciences NASDAQ:IDYA

$21.37 -0.92 (-4.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$21.38 +0.02 (+0.07%)

As of 06/27/2025 07:29 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time